Abstract
Antenatal glucocorticoid administration in order to prevent neonatal respiratory distress syndrome (RDS) has been an established regimen for over 15 years [1]. Use of such therapy is indicated in all cases in which premature delivery is expected or medical reasons require it [2]. Nevertheless, this treatment is only effective to a limited extent and, as before, a considerable number of premature children die of pulmonary complications. Therefore every obstetric unit has to re-evaluate the data in this particular field from time to time.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Liggins, G. C. and Howie, R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515.
Lorenz, U. Antepartale Lungenreifebestimmung durch Fruchtwasseranalyse, Berlin-Heidelberg-New York: Springer-Verlag, 1982.
Papageorgiou, A. N., Colle, E., Farri-Kostopoulos, E. and Gelfand, M. M. Incidence of respiratory distress syndrome following antenatal betamethasone: role of sex, type of delivery and prolonged rupture of membranes. Pediatrics 1981; 67: 614–17.
Editor information
Editors and Affiliations
Copyright information
© 1991 Macmillan Publishers Limited
About this chapter
Cite this chapter
Ragosch, V., Lorenz, U., Arabin, B., Jürgens, S., Weitzel, H. (1991). Antenatal glucocorticoid treatment in the prevention of neonatal RDS. In: Cosmi, E.V., Di Renzo, G.C., Anceschi, M.M. (eds) The Surfactant System of the Lung. Palgrave, London. https://doi.org/10.1007/978-1-349-12553-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-349-12553-1_11
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-12555-5
Online ISBN: 978-1-349-12553-1
eBook Packages: EngineeringEngineering (R0)